Recent Updates
Recently added Catalysts
GRAL Positive Sentiment Score: 75/100

GRAIL to Announce Second Quarter 2026 Financial Results

Key Takeaway: GRAIL, Inc. will announce its financial results for the second quarter of 2026 on August 5, 2026. Following the announcement, a conference call and webcast will be held to discuss the results and business developments. The event is open to all interested parties, and registration is encouraged for timely connection.

Market Sentiment Analysis

POSITIVE FACTORS

  • GRAIL is focused on early cancer detection, enhancing treatment outcomes.
  • The upcoming financial results may indicate positive business progress.
  • The company utilizes advanced technologies for cancer detection.

Full Press Release Details

MENLO PARK, Calif., July 29, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2026 following the close of market on Wednesday, Aug. 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.

Second Quarter 2026 Webcast and Conference Call Details

A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com.
Please register for the live event at https://grail-q2-financial-results-2026.open-exchange.net/.
To ensure timely connection, please register for the teleconference and join the webcast at least ten minutes before the scheduled start of the call. The live webcast and recorded replay are open to all interested parties.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
For more information, visit grail.com.

Frequently Asked Questions

When will GRAIL announce its Q2 2026 financial results?

GRAIL will announce its Q2 2026 financial results on August 5, 2026.

What time is the GRAIL conference call?

The conference call will take place at 1:30 p.m. PT / 4:30 p.m. ET.

How can I access the GRAIL webcast?

The webcast can be accessed through the investor relations section of GRAIL's website.

What is GRAIL's mission?

GRAIL's mission is to detect cancer early when it can be cured.

Last updated: Jul 29, 2026